Clinical Trial Update: A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase II trial results for MK-2206, an Akt inhibitor, in recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian Sarcoma
• Peritoneal Cancer

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ovarian Sarcoma, Recurrent Fallopian Tube Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-24